Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Labetalol
Drug ID BADD_D01236
Description Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture.[L7730] Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984.[L7724]
Indications and Usage For the management of hypertension (alone or in combination with other classes of antihypertensive agents), as well as chronic stable angina pectoris and sympathetic overactivity syndrome associated with severe tetanus. Labetalol is used parenterally for immediate reduction in blood pressure in severe hypertension or in hypertensive crises when considered an emergency, for the control of blood pressure in patients with pheochromocytoma and pregnant women with preeclampsia, and to produce controlled hypotension during anesthesia to reduce bleeding resulting from surgical procedures.
Marketing Status Prescription; Discontinued
ATC Code C07AG01
DrugBank ID DB00598
KEGG ID D08106
MeSH ID D007741
PubChem ID 3869
TTD Drug ID D0A8XN
NDC Product Code Not Available
Synonyms Labetalol | Labetolol | Albetol | Apo-Labetalol | Apo Labetalol | ApoLabetalol | Trandate | Labetalol Hydrochloride | Hydrochloride, Labetalol | Normodyne | Presolol | SCH-19927 | SCH 19927 | SCH19927 | AH-5158 | AH 5158 | AH5158 | Dilevalol | Labetalol, (R,R)-Isomer | R,R-Labetalol | R,R Labetalol
Chemical Information
Molecular Formula C19H24N2O3
CAS Registry Number 36894-69-6
SMILES CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Adverse drug reactionCytochrome P450 2D6P10635T57392Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lichen planus23.03.08.001--Not Available
Liver function test abnormal13.03.01.013--Not Available
Local swelling08.01.03.013--Not Available
Loss of consciousness17.02.04.004--Not Available
Loss of libido19.08.03.003--Not Available
Malaise08.01.01.003--
Mesenteric artery thrombosis24.01.08.003; 07.15.02.008--Not Available
Mood swings19.04.03.001--Not Available
Muscle spasms15.05.03.004--
Myopathy toxic15.05.05.006; 12.03.01.035--Not Available
Nasal congestion22.04.04.001--
Nausea07.01.07.001--
Nightmare19.02.03.003--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Pain08.01.08.004--
Palpitations02.01.02.003--
Paraesthesia17.02.06.005--
Peyronie's disease21.12.01.002--Not Available
Pruritus23.03.12.001--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Respiratory distress22.02.01.012--Not Available
Sensory loss17.02.07.007--Not Available
Shock24.06.02.002--Not Available
Skin lesion23.03.03.010--Not Available
Sleep disorder19.02.04.001--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Strangury20.02.02.017--Not Available
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages